Macrogen (038290), a genome sequencing firm, announced on Sept. 21 that it has gained a patent for extracting fusion protein that encodes RET fusion protein which can be used as a diagnostic marker of cancer. The patent includes primer pair of base sequence to detect KIF5B fusion protein and composite to inhibit activation of relevant fusion protein of lung cancer. By Yun Jeong-hyeon (clareyun@heraldcorp.com)